Hologic sees strong Q1 growth in non-COVID diagnostics revenues

By LabPulse.com staff writers

January 10, 2022 -- Hologic posted mixed preliminary financial results for the first quarter of its fiscal 2022 as year-over-year increases in its diagnostic business due to COVID-19 slowed, but diagnostics sales outside of coronavirus testing grew almost 10%.

For the first quarter (end-December 25), Hologic posted overall revenues of approximately $1.471 billion, down 8.6% compared with $1.609 billion for the same period in 2021. The company did not report net income in the preliminary results.

Revenue in the firm's Diagnostics division dropped by 15.8%, from $1.128 billion in the same period in 2021 to $950.4 million in the first quarter of fiscal 2022. The company said the Diagnostics business delivered "exceptional" performance, as the division "over delivered" on its base business while meeting heavy demand for testing for COVID-19. Excluding COVID-19 testing, the division's revenues grew 9.9%.

Hologic plans to release its full financial results for the first quarter on February 2.

Hologic adds SARS-CoV-2 test to global testing project
Hologic has added its Aptima SARS-CoV-2 assay to the company's Global Access Initiative, a program that is intended to expand access to critical diagnostic...
Hologic receives CE Mark for Genius cervical cancer software
Hologic has received the CE Mark for its Genius Cervical AI software for cervical cancer screening. The software uses artificial intelligence to analyze...
Hologic posts slight Q4 revenue decrease
Hologic posted a slight decrease in revenue for the company's fourth quarter, which it attributed to lower demand for its SARS-CoV-2 assays compared with...
Hologic launches multiplex COVID/flu assay
Hologic's Aptima SARS-CoV-2/flu assay is now commercially available in North America and Europe for the simultaneous detection and differentiation of...
Hologic launches on-demand molecular testing in Europe
Hologic has launched its Novodiag on-demand molecular test for infectious diseases and antibiotic resistance in Europe.

Copyright © 2022 LabPulse.com

Last Updated bc 1/10/2022 1:49:26 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current